veltuzumab: Clinical Trials

9 trials of veltuzumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 4, Terminated 3, Unknown 1, Withdrawn 1
Phase 18Completed 4, Terminated 2, Unknown 1, Withdrawn 1

Follow veltuzumab: new trials by email Literature Review of veltuzumab trials Research Report on veltuzumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Veltuzumab - Rheumatoid Arthritis
Phase 2TerminatedTakeda3002011-08-012016-04-13
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
90Y-epratuzumab tetraxetan, veltuzumab - Follicular Lymphoma
Phase 1 / Phase 2TerminatedWeill Medical College of Cornell University42010-10-012018-02-22
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab - Non Hodgkin's Lymphoma, NHL
Phase 1 / Phase 2WithdrawnGilead Sciences2010-05-012021-08-18
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab - Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Phase 1 / Phase 2UnknownQueen Mary University of London552010-01-012014-07-14
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
milatuzumab, veltuzumab, Correlative/Special Studies - Lymphoma
Phase 1 / Phase 2CompletedBeth Christian352009-09-012017-02-06
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
veltuzumab - NHL, Lymphoma, Non-Hodgkin
Phase 1 / Phase 2CompletedGilead Sciences322008-01-012021-08-16
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
veltuzumab - Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
Phase 1 / Phase 2TerminatedGilead Sciences482007-11-012021-08-16
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
hA20-humanized anti-CD20 antibody - Non-Hodgkin's Lymphoma
Phase 1 / Phase 2CompletedGilead Sciences822004-09-012021-08-17
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
veltuzumab - Non-Hodgkin's Lymphoma, Lymphoma, Diffuse
Phase 1 / Phase 2CompletedGilead Sciences392004-03-012021-08-18

Conditions studied

Lymphoma, Follicular (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Arthritis, Rheumatoid (1)  ·  Burkitt Lymphoma (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Prolymphocytic (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)

Sponsors

Gilead Sciences (5)  ·  Beth Christian (1)  ·  Queen Mary University of London (1)  ·  Takeda (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (7)  ·  United Kingdom (3)  ·  Argentina (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Mexico (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

William Wegener, MD, PhD (4)  ·  Beth Christian, MD (1)  ·  Matthew Smith, Doctor (1)  ·  Peter Martin, MD (1)  ·  William Wegener, MD, PHD (1)

Results publications

PMID 19451441, PMID 21173095, PMID 23829485, PMID 25847298, PMID 26389849, PMID 27515248